Quick Answer
AYTU BIOPHARMA, INC reported Gross Profit of $45.83 million for fiscal year 2025.
AYTU BIOPHARMA, INC Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2025 | $45.83M | -6.6% |
| 2024 | $49.05M | -26.4% |
| 2023 | $66.63M | +27.4% |
| 2022 | $52.28M | +79.1% |
| 2021 | $29.20M | +50.9% |
| 2020 | $19.35M | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $9.62M | -10.8% | +4.8% |
| September 30, 2025 | $9.19M | -23.4% | -28.3% |
| March 31, 2025 | $12.81M | +23.6% | +18.7% |
| December 31, 2024 | $10.79M | -26.1% | -10.0% |
| September 30, 2024 | $11.98M | -8.1% | +15.7% |
| March 31, 2024 | $10.36M | -18.7% | -29.0% |
| December 31, 2023 | $14.60M | -15.6% | +12.0% |
| September 30, 2023 | $13.04M | -27.7% | +2.3% |
- AYTU BIOPHARMA, INC showed a decrease of -6.6% in Gross Profit compared to the prior fiscal year.
- Over the 2020–2025 period, AYTU BIOPHARMA, INC’s gross profit has grown by 136.8% (from $19.35 million to $45.83 million).
- The most recent figure is from AYTU BIOPHARMA, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: